# 1st Gen Model Bristol-Myers Squibb Company Pharmaceutical preparations
at 21-aug-2017
BMY
Model's trade recommendations 2.11% Return for period
-5.24% Annual return
$92.52B Market Cap
β 1.17
BMY
Model (following trade recommendations)BMY
Underlying stockS&P 500
Index- 1.56 (2.77%) Div (Yield)
- BUY Analysts consensus recommendation
Bristol-Myers Squibb Company is a global leader in the research and development of innovative lifesaving and life-enhancing treatments for heart disease; high blood pressure; stroke; diabetes; cancer; HIV/AIDS and other infectious diseases; depression, schizophrenia and other mental disorders; pain; and other conditions.
Industry sector: Medical
Sector classification: Pharmaceutical preparations
Deep Learning based analysis and prediction model for Bristol-Myers Squibb Company (BMY) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.
Model is in the production pipeline since Oct. 2, 2015.
Market data for BMY model training are being downloaded from the Quandl premium datasets on a daily basis.
Model is being retrained on a daily basis.
| Float | 1636M |
| P/E | 18.93 |
| Shares Outstanding | 1640M |
| % Held by Insiders | 0.23% |
| % Held by Institutions | 69.68% |
| EPS (last reported FY) | $2.83 |
| EPS (last reported Q) | $0.74 |
| EPS, estimated (last reported Q) | $0.73 |
| Total revenues | $19 B |
| Net income | $4 B |